Skip to content

BioArctic’s Chairman of the Board Wenche Rolfsen declines re-election


Stockholm, January 19, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Chairman of the Board of Directors, Wenche Rolfsen, has informed the Nomination Committee that she declines re-election at the company’s Annual General Meeting on June 1, 2023. The Nomination Committee has started the work to find a replacement, and will present its proposal for the composition of the Board, including a new Chairman, well ahead of the Annual General Meeting. Wenche Rolfsen was elected to BioArctic’s Board of Directors in 2016 and has served as Chairman of the Board since 2017.

“Wenche’s contribution to BioArctic’s excellent development in recent years has been of great importance. Under her leadership, BioArctic has been listed, and the organization has grown and developed from being a research company, to include development and a commercial organization. We would like to thank Wenche for her strong commitment and leadership over the past 7 years. She will leave behind a strong company, well equipped for the future,” said Lars Lannfelt and Pär Gellerfors, founders and main shareholders of BioArctic.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on January 19, 2023, at 09.50 a.m. CET.

For further information, please contact:
Oskar Bosson, VP Communications and IR
Phone: +46 70 410 71 80

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Large Cap (ticker: BIOA B). For more information about BioArctic, please visit